AstraZeneca (AZN -2.36%) might soon be on the hook for an eventual 11-figure payout, and investors weren't all that comfortable with this. A Bloomberg article published Thursday morning said that the company is pursuing what might end up being an expensive partnership with a biotech.A cautious market traded AstraZeneca stock down by more than 2% following the report, on a day when the S&P 500 index landed firmly in positive territory with a 0.8% gain.That's one big price tagThe article that dinged AstraZene ...